Introduction
Ten years ago, describing what is new in phospholipid signaling in ten pages of Cell would have been easy; it would have been essentially a summary of the phosphoinositidase C (PIC) story: phosphatidylinositol(4,5)bisphosphate (Ptdlns(4,5)P2) hydrolysis to inositiol(1,4,5)trisphosphate (Ins(1",4,5)P3), with the synergistic action of Ca 2÷ (mobilized by Ins(1,4,5)P3) and diacylglycerol (DAG) on protein kinase C (PKC) ( Table 1 ). As will become obvious below, the involvement of phospholipids in cell signaling is now enormously more complicated, and as more potential signaling systems emerge, it becomes even less clear as to which does what. With many of the systems, we are at a stage of ignorance similar to that in the late 1970's with PIC, confused and uncertain and largely lacking the tools and basic knowledge to build up the picture. So, with the limited space available we can make no attempt at comprehensive coverage, but we will try to summarize, mostly by specific examples, what we see as the crucial questions as things stand now. The preceding sentence should be taken as a plea for tolerance from workers whose papers we have not cited and who consequently feel slighted.
Inositol Lipids
We will not discuss the regulation of the plasma membrane-located PIC signaling system here. Its enzymology and regulation and the enormous complexities of Ins (1,4,5)P3 action have been adequately dealt with in numerous reviews (Berridge, 1993; Rhee and Choi, 1992; Clapham, 1994 [this issue of Cell]). The big unknowns in inositol lipid function that we will deal with lie in three principal areas: 3-phosphorylated inositol lipids; Ptdlns(4,5)P2 and the cytoskeleton; and nuclear inositides.
3.Phosphorylated Inositol Lipids
This is the major inositide signaling system of the moment, to judge from investment of time and money. The cast of characters is shown in Figure 1 , and there have been several extensive reviews recently (Stephens et al., 1993a; Kapeller and Cantley, 1994) . Although we still do not know what the physiological functions of 3-phosphorylated lipids are, there has been a considerable lifting of the mist surrounding them recently. One potential source of confusion that is just being clarified is the appearance that evolution has had (at least) two bites at the 3-phosphorylated inositol lipid cherry: 3-phosphorylation of Ptdlns and of Ptdlns(4,5)P2 are probably controlled by different enzymes for different physiological functions. Let us make clear the distinction between a phosphoinositide 3-kinase (PI3-kinase) and a Ptdlns 3-kinase: the former can phosphorylate any inositol lipid in vitro, and we have to investigate by indirect means what substrate(s) it actually uses in the intact cell (as discussed below, the predominant substrate turns out to be Ptlns(4,5)P2). The latter enzyme is what it says, a Ptdlns-specific 3-kinase.
Radiolalabeling experiments have shown that in intact cells, the principal route of Ptdlns(3,4,5)P3 synthesis is by 3-phosphorylation of Ptdlns(4,5)P2 (Figure 1 ; Hawkins et al., 1992; Stephens et al., 1993a) . Since many signal transduction pathways activate PI3-kinase, these experiments focus attention on Ptdlns(3,4,5)P3 as a potential second messenger. Although the possibility of an alternative route of Ptdlns(3,4,5)P3 synthesis in platelets has been described (Cunningham et al., 1990) , recent experiments on the same tissue make this an unlikely possibility (Carter et al., 1994) . (The latter group labeled the cells for a very short time with 32p~ [i.e., nonequilibrium labeling], and this is critical for determination of inositide sythesis pathways by this method [Stephens and Downes, 1991] ). The likelihood that PI3-kinase will in vivo phosphorylate mainly Ptdlns(4,5)P2, although in vitro it will phosphorylate Ptdlns, Ptdlns(4)P, and Ptdlns(4,5)P2, has remarkable parallels with properties of the PIC family; many of these show similar differences in specificity between the test tube and the intact cell (Rhee and Choi, 1992) . This parallel with PIC is further strengthened by the recent demonstration of a distinct PI3-kinase (presumably a Ptdlns(4,5)P2 3-kinase in vivo) that is not controlled through tyrosine kinase activity, but rather by G proteins (Stephens et al., 1994a) ; the PIC enzymes can be classified into distinct families regulated by, for example, G proteins (13 family) and tyrosine kinases (7 family), and it is very likely that the PI3-kinases will show a similar type of grouping.
The cloning of the catalytic subunit (p110) of mammalian PI3-kinase revealed homology with the yeast VPS34 gene (Hiles et al., 1992) , which is involved in vacuolar protein processing (Herman and Emr, 1990) . However, it was puzzling that this yeast enzyme will only phosphorylate Ptdlns in the test tube and shows no activity against Ptdlns(4)P or Ptdlns(4,5)P2 (Kodaki et al., 1994a) ; this is consistent with the absence (thus far) of detectable Ptdlns(3,4,5)P3 in yeast. What could have been a confusing picture has fortunately been clarified by Stephens et al. (1994b) , who showed that mammalian cells also have a Ptdlns-specific 3-kinase, distinct from the several other activities that will phosphorylate Ptdlns, Ptdlns(4)P, and Ptdlns(4,5)P=. It is a logical conclusion that this new enzyme is the true mammalian vps34 homolog, and so it seems likely that whatever function Ptdlns-3 phosphorylation serves in yeast, it probably still serves in animals and that the phosphorylation of Ptdlns(4,5)P2 is for a different function that evolved after the split of yeast (and possibly also Chlamydomonas [Munnik et al., 1994] ) from the animal evolutionary lineage. So, if Ptdlns(3)P and Ptdlns(3,4,5)P3 serve different functions, what of Ptdlns(3,4)P2; is it a mere breakdown product? A Ptdlns(3)P 4-kinase has been shown to be dis- The nomenclature used here makes clear the distinction between the general phosphoinositide and the specific phosphatidylinositol designation. The reasons for this are discussed in the text. Note that for reasons of history and journalistic style, molecules referenced in this study do not always follow this distinction. Other common abbreviations used have been noted.
tinct from PI3-kinase or Ptdlns 4-kinase (Graziani et al., 1992) , and in a higher plant species, this route of synthesis of Ptdlns(3,4)P2 may be the predominant one (Brearly and Hanke, 1993 Wennstr6m et al. (1994) . Their data and those of others (Kotani et al., 1994) imply the involvement of Ptdlns(3,4,5)P3 in membrane ruffling, and WennstrSm et al. (1994) have pointed out that the common factor in membrane ruffling (Ridley et al., 1992) and in two other processes in which Ptdlns(3,4,5)Ps is probably involved (e.g., superoxide generation in neutrophils [Segal and Abo, 1993] and possibly glucose transport control in adipocytes) is the small G protein, rac. On this basis, Wennstr6m et al. (1994) have suggested that rac is a, or the, primary target of Ptdlns(3,4,5)Pa. Although increases in the 3-phosphorylated lipids has dominated the focus of research into the activation of this pathway, it should not be forgotten that the tyrosine kinase-stimulated PI3-kinase is a dual specificity enzyme. It is not only able to phosphorylate phosphoinositides, but it is also able to act as a serine/threonine protein kinase. This is demonstrated by p110-regulated phosphorylation of its own p85 regulatory subunit (Carpenter et al., 1993; Dhand et al., 1994) . Initially, it was shown that phosphorylating the 85 kDa subunit led to a decrease in the lipid 3-kinase activity of the enzyme, so this was suggested as a mechanism for autoregulation. However, data in a recent paper by Lam et al. (1994) suggest that PI3-kinase, in an insulin-dependent fashion, is also able to phosphorylate insulin receptor 1. Whether the G protein-sensitive PI3-kinase will also turn out to be a serine/threonine kinase remains to be determined, but if not, this could potentially differentiate between the activation of the PI3-kinase pathway by G proteins versus its control by tyrosine kinases.
To complicate matters further, two groups (RodriguezViciana et al., 1994; Kodaki et al., 1994b ) have now identified yet another mechanism by which PI3-kinase can be activated. It appears that ras, in its activated GTP-bound state, can not only activate Raf and subsequently mitogenactivated protein kinase, but it also can interact and associate directly with PI3-kinase, leading to enhanced activation and increased production of 3-phosphorylated lipids in intact cells. In addtion, N17 dominant negative ras leads to a 5-fold decrease in the levels of Ptdlns(3,4,5)Pa induced by epidermal growth factor (EGF) (Rodriguez-Viciana et al., 1994) , suggesting that in intact cells, ras is a major regulator of 3-phosphorylated lipid production.
Finally, it is a fair bet that an important tool in the clarification of Ptdlns(3,4,5)P3 function will be the fungal metabolite, wortmannin. This compound, at suitably low concentrations, seems to be a remarkably specific inhibitor of Pl3-kinase (Arcaro and Wymann, 1993) but not of yeast or mammalian PI3-kinase (Stephens et al., 1994b) . In addition to being a useful experimental compound, it will surely be looked at again from a pharmaceutical angle, this time with the idea of exploiting these signaling pathways.
Ptdlns(4,5)P2 and the Cytoskeleton
As Janmey (1994) has pointed out in his recent review on the interactions of polyphosphoinositol lipids and the cytoskeleton, tight binding of these lipids to proteins has been known for a long time and may involve a wide range of components of the cytoskeletal system. The strongest and most studied interactions, with ~.heir physiological endpoints most clearly indicated, are those first discovered, i.e., the interactions of Ptdlns(4,5)P2 with gelsolin and with profilin (Lassing and Lindberg, 1985; Janmey and Stossel, 1987) .
Following the initial discovery of these interactions, it would be fair to say that there was considerable skepticism about their significance among the inositide signaling community. This was for several reasons, but in particular because of the absence of any evidence of specificity in the binding (as there is no suitable control) and the difficulty in accepting that the receptor-mediated hydrolysis of inositol lipids would be important in these processes. (In other words, Ptdlns(4,5)P2 would seem to have enough to do as a precursor to Ins(1,4,5)P3, DAG, and now Ptdlns (3,4,5)P3, and for it to do something else as well seemed to make excessive demands on the ability of the cell to regulate functions independently).
However, there is now an increasing realization that inositides in the cytoskeleton are probably a separate issue entirely from those in the plasma membrane. The enzymes responsible for their synthesis are in part bound to the cytoskeleton, an interaction that can be changed upon cell activation (Payrastre et al., 1991) . Also, it has become apparent that the synthesis of the polyphosphoinositol lipids can be controlled directly by receptors and is not just an indirect consequence of PIC activation (Stephens et al., 1993b) . Thus, the regulation of inositide kinases in the cytoskeleton is something that can now be considered as a system separate from those in the plasma membrane.
Thus far, much of the work carried out on the regulation of cytoskeletal elements by polyphosphoinositides has focused on in vitro characterization of binding sites on components such as gelsolin, profilin, and cofilin (reviewed by Janmey, 1994) . In a farsighted review, Lassing and Lindberg (1988) had already suggested that Ptdlns(4)P/ Ptdlns(4,5)P2 bound to profilin could inhibit the production of profilactin complexes and therefore could release monomeric actin able to form new filaments.
Perhaps the most enticing piece of evidence for a role of Ptdlns(4,5)P2 bound to profilin in the control of cytoskeletal events comes from some elegant work carried out by the Wigler group (Vojtek et al., 1991 ) using a yeast mutant in cyclase-associated protein (CAP). CAP is a bifunctional protein required for both RAS signaling to the adenylyl cyclase complex and an adenylyl cyclase-independent pathway. The CAP mutant phenotype is associated with both nutritional and morphological defects, and Vojtek et al. (1991) screened for genes able to suppress the second phenotype. Profilin was identified in this screen. Comparison of the homology of yeast profilin with profilins from Acanthamoeba revealed two limited homology boxes, and mutations introduced into these boxes lead to a decrease in the ability of the yeast profilin to suppress the CAP mutant. However, biochemical analysis revealed that all mutant profilins bound actin with an affinity similar to that of wild-type profilin, suggesting that another function of profilin was important in complementing CAP. Vojtek et al. (1991) therefore investigated the ability of the two isoforms of profilin from Acanthamoeba to suppress the CAP phenotype, and they demonstrated that, by far, the most effective was profilin isOform II, which (although highly homologous to isoform I) has a 10-to 50-fold higher affinity for Ptdlns(4,5)P2 (Machasky et al., 1991) . The demonstration that CAP is also present in pig platelets and is an actinbinding protein (Gieselmann and Mann, 1992) suggests that a similar signal transduction pathway may exist in mammals.
For the profilin-Ptdlns(4,5)P2 interaction to be an important link in the PI cycle and the regulation of actin filaments, Lassing and Lindberg (1988) had suggested that PIC would be able to recognize and hydrolyze Ptdlns(4,5)P2 bound to profilin. A number of years later, GoldschmidtClermont et al. (1991) demonstrated not only that profilin inhibited PIC from hydrolyzing Ptdlns(4,5)P2, but also that this inhibition was relieved by phosphorylation of PIC. Thus, the ideas of Lassing and Lindberg (1988) have been vindicated and suggest a way in which Ptdlns(4,5)P2 hydrolysis may lead to a remodeling of the cytoskeleton. Under resting conditions, PIC would be unable to hydrolyze Ptdlns(4,5)P2 owing to its protection by profilin. However, profilin-Ptdlns(4,5)P2 could be hydrolyzed following receptor stimulation, leaving profilin able to interact with actin filaments and perhaps lead to their breakdown and the production of profilin-actin complexes. Resynthesis of Ptdlns(4,5)P2 could then occur, as has been suggested by the demonstration that a number of lipid kinases, including Ptdlns(4)P 5-kinase, translocate to the cytoskeleton after receptor activation (Payrastre et al., 1991) . We should of course stress that Ptdlns(4,5)P2 metabolism by PIC is by no means the only way in which this cytoskeletal remodeling could occur. Agonists such as insulin have also been demonstrated to lead to a change in actin polymerization, probably through the activation of small molecular weight G proteins such as rac/rho (Ridley et al., 1992) , and the possibility of 3-phosphorylated inositol lipid involvement (Zhang et al., 1992 ) is one to be explored further. With regard to rho and the cytoskeleton, the recent suggestion by Chong et al. (1994) that rho can regulate Ptdlns(4)P 5-kinase provides a potential mechanism for regulation of Ptdlns(4,5)P2 levels.
Finally, some elegant work identifying the binding sites for Ptdlns(4,5)P2 on gelsolin and villin (Janmey et al., 1992) has shown that this is unlikely to be a fortuitous binding to a grouping of positively charged amino acids, but rather that it is probably a specific interaction. It will be fascinating, when Ptdlns(3,4)P2 and Ptdlns(3)P become available in quantity, to explore the isomeric specificity of this binding. And as the families of inositol lipid kinases grow, we view it as an increasingly enticing prospect that some of these could be specifically associated with the cytoskeleton and differentially regulated, for a purpose separate from what is currently regarded as "classic" inositol lipid signaling.
The Nuclear Inositide Cycle
This appears to us to be currently the most enigmatic aspect of inositide function. We have summarized elsewhere the evidence for the existence of a nuclear inositide cycle , which in its basic biochemistry (the controlled hydrolysis of Ptdlns(4,5)P2 and possibly also Ptdlns(4)P to DAG and inositol phosphates) resembles the plasma membrane inositide cycle. We have indeed wondered whether the nucleus was the site at which this classic PIC cycle evolved on the simple reasoning that if (as we suspect) the nuclear PIC cycle plays an important role in some aspect of nuclear function at one or more points in the cell cycle, then this is likely to have preceded cell surface receptor signaling in evolution.
In the context of the above discussion of inositol lipids binding to the cytoskeleton, it is particularly interesting that most of the data suggest that the enzymes and lipids of the nuclear cycle are all bound to the nuclear skeleton rather than being located in the nuclear membrane. In our hands (but not those of , the nuclear membrane must be removed from the nuclei before it is possible to detect changes in DAG or Ptdlns(4,5)P2 and our interpretation of this has been that it is only inositides within the nucleus (not in the detergent-soluble nuclear membrane) that are involved in the nuclear inositide cycle . If the Ptdlns(4,5)P2 that is the substrate for the nuclear PIC is not in a lipid bilayer, but is bound to a protein, then the parallel with the hydrolysis of Ptdlns(4,5)P2 bound to profllin, discussed above, is obvious.
What are as yet far from obvious are the answers to the key questions that the existence of a nuclear inositide cycle poses: how is it controlled, and what is it doing? Because coincident with DAG generation in the nucleus is a translocation of PKC into the nucleus , we could argue that the answer to the latter question is the following: it produces an activated PKC inside the nucleus. But that in turn only invokes more questions; e.g., how does the cytosolic PKC "see" the nuclear DAG if the DAG is not in the nuclear membrane. (And then, how does PKC get translocated into the nucleus since there is no obvious nuclear translocation signal?) Additionally, what is the substrate for PKC once it is in the nucleus in an activated state? One group has been building up an impressive body of evidence for the involvement of PKC II in lamin phosphorylation, and recent data (Goss et al., 1994) have further advanced the idea that lamin B is the true physiological substrate by identifying the phosphorylation sites. What is particularly fascinating about this is that Goss et al. (1994) suggest that PKC is not in itself sufficient to cause nuclear envelope breakdown, but another kinase (cdc2, perhaps) is probably also required. On the other hand, the absence of one lamin phosphorylation site in vivo, which PKC does phosphorylate in vitro, leaves it open still to discussion whether or not PKC has a physiological role to play in this process.
If lamin phosphorylation is indeed a part of nuclear inositide function, then it may not be the only one. First, the timing of the major rise in nuclear DAG and drop in inositol lipids in vivo (Banfib et al., 1993) and in coordinated cell cultures ) is more coincident with S phase than with envelope breakdown, suggesting an alternative function. Second, Ptlns(4)P and Ins(1,4)P2 can activate DNA polymerase ~ in vitro (Sylvia et al., 1988) , and very recent data from showing that superinduction of an (apparently partly nuclear) Ins(1,4)P2 1-phosphatase led to some suppression of DNA synthesis are certainly consistent with an intranuclear second messenger role for Ins(1,4)P2. Third, it is unclear whether the Ins(1,4,5)P3 that is apparently involved in nuclear envelope reassembly (Sullivan et al., 1993 ) is produced from cytosolic or from nuclear Ptdlns(4,5)P2; if the latter is indeed bound to the nucleoskeleton, there is no a priori reason why the nuclear inositide cycle should not be already functional even before the nuclear membrane is fully assembled.
We do not yet know whether all production of DAG within the nucleus is from inositides or whether other lipids contribute. Jarpe et al. (1994) have shown that phosphatidylcholine (PtdCho) is the major contributor to an increase in nuclear DAG, but the nuclei they isolated still had nuclear membranes attached, and it is likely that the PtdCho hydrolysis they observed occurred in the nuclear membrane rather than within the nucleus.
PtdCho Hydrolysis
In this area, the data are currently very confusing; at least with Ptdlns(4,5)P2 breakdown, we know that it is a PIC that is involved and that the breakdown is probably predominantly in the plasma membrane. With PtdCho as a source of lipid second messengers, the hydrolysis can be by phospholipase A2 (PLA2), PLC, or PLD (Figure 2 ). It is not always clear which one; it may often be all three, and we do not know the subcellular location(s).
PtdCho hydrolysis has recently been extensively reviewed by Exton (1994) , and we do not intend to repeat this impressive feat here. Instead, to illustrate how progress has been made in understanding which phospholipase hydrolyzes PtdCho in a given situation and why this is so confusing, we will focus on a single series of experiments conducted on NIH 3T3 cells by Cook and Wakelam (1992) . The background to the experiments was in part the observation by Bonser et al. (1989) that phosphatidic acid (PtdOH) produced by PLD hydrolysis of PtdCho in neutrophils is =trapped" by increasing addition of ethanol (such that phosphatidylethanol is produced because ethanol substitutes for water in the nucleophilic attack on the phosphodiester bond). The resulting reduction in DAG levels and the effect on physiological responses should give answers to the following questions: how much of the DAG generated is actually derived from PtdOH hydrolysis (the PtdOH having been first produced by PLD [ethanol does (Bonser et al., 1989) , the answers were reasonably clear: sufficient ethanol to maximize phosphatidylethanol production from PtdCho (but with no effect of Ptd(4,5)P2 hydrolysis) completely inhibited DAG production from PtdCho and it also inhibited superoxide generation. This suggested that all the DAG was derived via PLD (such that there is little PLC activity on PtdCho), and it also suggested that PLD activation was an essential part of the physiological response to an agonist that activates superoxide generation. The latter does not of course distinguish between whether the DAG or PtdOH is the more important second messenger (subsequent correlative studies imply that PtdOH is the more likely of the two [Bauldry et al., 1991] ). Against this (comparatively) simple background, Cook and Wakelam (1992) explored the source of DAG in NIH 3T3 cells stimulated by three agonists, all of which could be shown to activate PLD: tetradecanoyl phorbol acetate, bombesin (which interacts with a G protein-linked receptor), and EGF (whose receptor contains a tyrosine kinase). Increasing ethanol in the incubations with tetradecanoyl phorbol acetate as the stimulus gave an answer not unlike the neutrophils: sufficient ethanol to trap all the PtdOH effectively prevented DAG generation from PtdCho. The PtdCho source in this system is revealed, as in other systems, by fatty acyl profiles (Pettit et al., 1994) . However, with bombesin, maximal inhibition with ethanol only prevented 50% of the DAG generation, and with EGF, there was virtually no effect of ethanol on stimulated DAG production at all, despite evidence for strong stimulation of PLD. Thus, there must also be PLC hydrolysis of PtdCho going on independently of PLD activation, but to differing degrees depending on the agonist. Even this simple set of experiments on one cell type already provides a complex picture, and there are still further questions that need to be investigated even in this system, such as the subcellular location of PtdCho hydrolysis, how hydrolysis is controlled, and the physiological functions of DAG and PtdOH. Extending the view to the mass of data on other tissues (Exton, 1994 ) emphasizes how far we still have to go.
Not least of the problems is that we are still at a very early stage in our knowledge of the enzymology of PLD and PLC, and this is something being addressed now in many laboratories. Also, we know that DAG can stimulate PKC, but knowing which isozymes (the Ca 2+ independent variety, perhaps) and where they are is currently no more than guesswork. There are a number of well-explored possibilities for what PtdOH may do as an intracellular second messenger (e.g., regulation of rasGAP, control of neutrophil superoxide generation, and regulation of actin polymerization [Exton, 1994] ), but these are not yet firmly established in vivo. Frequently, there is no obvious control for the effects of PtdOH in vitro; would the sn-2,3-enantiomer be a help here?
With PLA2, our knowledge of the enzymology is more extensive, and the control of PLA2 activities by Ca 2+, phosphorylation, and G proteins has also been reviewed recently (Exton, 1994) . The liberation of arachidonic acid will engender eicosanoids, and the physiological importance of these compounds as autocrine or paracrine regulators is well established (Piomelli, 1993) . What is still not very clear is whether arachidonic acid itself is a physiological messenger of importance. That it will stimulate some PKC isozymes in vitro is known (Hug and Sarre, 1993 ), but we do not yet know when and where this is relevant in vivo. There are also plenty of data suggesting it can act as a retrograde second messenger in the nervous system, in part by regulating ion channels (Piomelli, 1993) . However, in most investigations of arachidonic acid function, other unsaturated fatty acids (when tried) can do the same thing. The unique aspects of arachidonic acid are that it Js at a very low resting level in cells compared with these other unsaturated fatty acids, it is very much the preferred substrate for conversion to eicosanoids, and there is evidence for arachidonoyl-specific phospholipases. Perhaps it is worth a thought, however, that this unusual behavior may all be geared solely to its conversion to eicosanoids and that the proposed second messenger functions of arachidonate that do not require such a conversion may sometimes be fulfilled physiologically by other unsaturated fatty acids.
Finally, it is obvious that PtdCho has been the major focus of studies on alternative (i.e., noninositide) sources of DAG, PtdOH, and fatty acids. In some systems, ethanolamine lipids (either diacyl or alkenyl versions) have also been examined and have been found to be insignificant as a source. However, in other studies (Kramer and Deykin, 1983; McNulty et al., 1991) , ethanolamine lipids have been suggested to make a significant contribution to DAG, PtdOH, or fatty acid generation, and these lipids, in the past generally neglected, may be due for a reinvestigation.
Sphingolipid Signaling
This is one of the most exciting and unexpected areas of phospholipid signaling to emerge in recent years. It has been the subject of several reviews (Hannun, 1994; Kolesnick and Golde, 1994) , and here we can do no more than what we have done above for other topics; that is, to sum-marize briefly our own perception of where we stand, and to point to what we see as major areas of confusion. Sphingomyelin is predominantly (but not exclusively; reviewed by Koval and Pagano, 1991) a plasma membrane lipid and accumulates in large quantities in myelin. Thus, in the past, much of the interest in it (as with Ptdlns(4,5)P2 in the 1960's and 1970's) was as a structural component. Only recently has it been perceived as an actively metabolized lipid with the potential to generate second messengers.
Probably the most burning question is, just how many of those messengers are there? (Ptdlns(4,5)P2 certainly generates three: Ins(1,4,5)P3, DAG, and Ptdlns(3,4,5)P3, with Ins(1,3,4,5)P4 as an optional fourth; thus, there is precedence for the generation of multiple messengers). Figure 3 shows a schematic structure for sphingomyelin (with R being the fatty acyl chain, which, as with all phospholipids, is variable), and the different boxes show the different bits, which we will discuss with respect to potential messenger functions. Not least of the problems with this area is that we do not yet have a full understanding of the catabolic enzymology that generates these bits of the parent molecule.
The synthesis of sphingomyelin is well summarized in other reviews (Koval and Pagano, 1991; Hannun, 1994 ), but we think it would help the reader not familiar with the topic to point out that the last stage in de novo synthesis of ceramide (which then, in turn, is converted to sphingomyelin by the addition of a phosphocholine moiety) is the introduction of the trans-unsaturated bond highlighted by the arrow in Figure 3 . The available data on the specificities of the actions of the various portions of sphingomyelin that are discussed below all suggest that homologs lacking this trans-unsaturated bond are inactive. Thus, as far as we know, the cell does not confuse precursors in de novo synthesis with breakdown products; only the latter are biologically active. Note that the phosphoinositide signaling system in general maintains a similar distinction (e.g., Ins(1,4,5)P3 is only produced as a second messenger from Ptdlns(4,5)P2). However, PtdOH and DAG are both intermediary metabolites of phospholipid synthesis, as well as being generated as second messengers, as described above. How the cell avoids confusing the two functions, anabolic intermediate versus second messenger, is still one of the mysteries of lipid signaling.
Sphingomyelinase and Ceramide
Sphingomyelinase catalyzes the parallel reaction to PLC, generating ceramide and phosphocholine (Figure 3 ; reviewed by Hannun, 1994; Hannun and Linardic, 1994; Kolesnick and Golde, 1994) . Sphingomyelinases are a growing family, and it is exciting to anticipate the elucidation of molecular structures for this family; will there be G proteinand tyrosine kinase-regulated members (as with PIC), which are easily identified as such? The clear decrease in sphingomyelin that happens when cells are stimulated by the appropriate agonist (e.g., tumor necrosis factor or interleukin-1 reviewed by Hannun, 1994] ), coincident with a parallel and near stoichiometric increase in ceramide, is entirely consistent with the activation of sphingomyelinase.
The evidence that ceramide, which could be viewed as the sphingolipid counterpart of DAG, is a second messenger is becoming strong and consistent. The use of a number of chemical analogs (which include versions with a short fatty acyl chain, a parallel with dioctanoylglycerol or oleoylacetylglycerol, to increase accessibility to intact cells) has convincingly established a specific role for this sphingolipid (Hannun, 1994) . The two most promising molecular targets for ceramide are a ceramide-stimulated protein kinase (Joseph et al., 1993 ) and a ceramide-stimulated protein phosphatase (Dobrowsky et al., 1993; Wolff et al., 1994) . Consideration of the types of agonists that appear to activate the sphingomyelin pathway (Hannun, 1994; Kolesnick and Golde, 1994) suggests a role for ceramide in antiproliferation; these agonists include tumor necrosis factor, interferon, interleukin-1, and also vitamin D3 (which in HL60 cells induced growth inhibition, followed by the induction of differentiation [Okazaki et al., 1990] ). Indeed, the effect of vitamin D3 was mimicked by the C2 (short fatty acyl chain) ceramide analog, which was also found to induce differentiation and to lead to the down-regulation of c-myc (Wolff et al., 1994) . C2 ceramide also mimicked the apoptotic response to tumor necrosis factor (~ in U937 cells (Obeid et al., 1993) . Some clarification will certainly be required concerning whether ceramide is a physiological activator of any PKC. Recent data from Lozano et al. (1994) has implicated PKC~ (by the use of dominant negative mutants) in the activation of NF-KB by ceramide, one of the most exciting potential regulatory influences of sphingolipid signaling. However, this in itself illustrates the confusion that can be generated, as in this system DAG also (via PKCr~) regulates NF-~B and is also generated by tumor necrosis factor ~ stimulation. So, we still have no idea whether the PtdCho or sphingomyelin PLC pathway is the controlling factor (i.e., are the DAG and ceramide pathways parallel and partly redundant or are they sequential, and if so, in which order? [see SchLitze et al., 1992] ). The attraction of the ceramidestimulated protein kinase (Joseph et al., 1993 ) is that it is not sensitive to DAG, suggesting that it is more likely to be a target for sphingolipid signaling. Since many of the agonists that stimulate sphingomyelinase also stimulate PLC activity on PtdCho, it is difficult to dissect these two pathways.
Sphingosine, Sphingosine Phosphate, and Sphingosine Phosphochofine
We consider these together because there is no absolutely definitive data as to which (if only one) is the active species or if they all are active (there is no reason why they should not be; DAG and PtdOH are both considered serious candidates as second messengers). Not least of the confusing aspects of sphingosine is the rather large number of events that it has been shown to stimulate (e.g., calcium release, EGF receptor tyrosine kinase, PLD; Desai et al., 1993; Olivera et al., 1994) . Also, we do not yet have a well-established receptor-controlled enzyme(s) that can generate sphingosine from sphingomyelin or ceramide. Without evidence that both an agonist and sphingosine can control the same event and, in addition, that the agonist can stimulate sphingosine production (i.e., the usual chain events that has to be linked for us to begin to accept a second messenger), it is difficult to know where to place sphingosine. Recently, this unfortunate set of circumstances may have begun to change. Olivera and Spiegel (1993) have shown stimulated production of sphingosine phosphate, a mitogenic effect of sphingosine and sphingosine phosphate, and an inhibition of the mitogenic effect of fetal calf serum and platelet-derived growth factor (but not EGF, which does not stimulate sphingosine phosphate production) by DL-threo-sphingosine (an inhibitor of sphingosine kinase), all on the same cells. Also, the stereospecificity of sphingosine isomers has very recently been explored (Olivera et al., 1994) with regard to its effects on cell growth, Ca 2+ release, and stimulated PLD activity (the last is thought to be an important part of the action of sphingosine). The resu Its suggest that some effects of sphingosine are stereospecific, whereas others are not, but there is sufficient stereospecificity in some responses to make it unlikely that the effects of sphingosine are entirely nonspecific.
However, thus far, the molecular targets of sphingosine and its relatives remain unidentified. Some recent data implicate AP-1 in intranuclear events coincident with mitogenesis induced by sphingosine (Suet al., 1994) , but how direct or indirect these effects of sphingosine are has not yet been investigated. Also, although sphingosine phosphate is (based on the sphingosine kinase inhibitor data above) the most likely candidate for being the active molecule in vivo, this is not firmly established. For example, sphingosinephosphorylcholine is a more potent mitogen than sphingosine or sphingosine phosphate (Desai et al., 1993) . Although this may just be because it can enter cells more easily, Desai et al. (1993) have suggested it acts by a route distinct from sphingosine or sphingosine phosphate.
Overall, there is a problem in that, thus far, the only way to generate sphingosine from sphingomyelin appears to be by activating the sphingomyetinase pathway to produce ceramide, followed by a ceramidase activity to generate sphingosine, and this begs the question of why this pathway is antiproliferative in some cells and mitogenic in others. One possibility is that the cells in which ceramide is an antiproliferative agent do not contain sphingosine kinase pathways, whereas in cells such as Swiss 3T3 fibroblasts, perhaps the receptor activation of a ceramidase leads to enhanced production of sphingosine, followed by sphingosine phosphate, which could then act mitogenically.
However, with our paucity of information about how cells generate sphingosine, which derivative(s) is(are) really the active species, and what agonists stimulate their production, a current assessment of how all this fits into the scheme of things is very difficult. Yet the influence of sphingolipids and what may be a whole family of new second messengers generated from them may be the next boom area in intracellular phospholipid signaling.
PKCs
The discussion of the activation of this large family of enzymes has been left until the end not least because, one way or another, they are involved in almost all of the sections discussed above. The PKC family has now been subdivided into three groups: the Ca 2÷ plus DAG requiring family, the DAG requiring family, and finally the atypical PKCs, which require neither (reviewed by Hug and Sarre, 1993) . In fact, the three subdivisions fit nicely into some of the signal transduction pathways already outlined: the classical PI pathway, which generates DAG and Ca 2÷, would obviously activate the first group, while PtdCho/PLC or PLD hydrolysis of PtdCho leading to just DAG would only activate the second group. Activation of the third group could be carried out by either the Ptdlns(3,4,5)P3 pathway (Nakanishi et al., 1993) or the ceramide pathway (see above). Although there is evidence for all these second messengers activating members of the PKC family, in vitro, this does not necessarily reflect what happens in vivo. Thus far, we still have a profound lack of knowledge as to which isozyme is controlled by what, where it is controlled, and which substrate(s) it phosphorylates in vivo. Not least of the problems is the ability of most PKC isozymes to be rather promiscuous in vitro with respect to both stimulants and substrates and correlating specific sites of phosphorylation with those used in vivo (for example, the work of Goss et al. (1994) that we mentioned in the section on nuclear inositides) has to be done in order to pin a precise physiological substrate on a particular PKC. Nevertheless, the use of dominant negative mutations, genetic knockout experiments, and overexpression are beginning to reveal, in a few instances, some precise and specific evidence for the role of particular PKC isozymes in defined physiological processes (Watanabe et al., 1992; Dominguez et al., 1993) .
We discussed above our uncertainties about the location and mechanism of generation of DAG from PtdCho, and it is obvious that if we understood that better, we might get a bit further in appreciating which PKCs are controlled by what. Some recent studies on piatelets show what kind of complications we may face (Fukami and Holmsen, 1995) . In these studies, resting platelets (which by standard criteria had no PKC activation) showed widely fluctuating DAG levels, and these were not greatly changed on activation by thrombin (which causes PKC activation). Only on purifying and analyzing separately all the DAG species does it emerge that the stearoyl-arachidonoyl species (derived solely from inositides, perhaps?) is the only one that is absent in resting platelets and increases following thrombin stimulation; thus, only that species correlates with PKC activation.
Conclusion
It is an inevitable consequence of a brief review of a very complex and new area that such a review appears rather negative and confused; what we do not know is so much more than what we do know. But these are enormously exciting times in phospholipid signaling. The inositides continue to blossom and expand into new territories of cell function. PtdCho (and perhaps the ethanol amine lipids?) is now unquestionably more than just a structural membrane lipid, and the same is now being said about sphingomyelin, regarded previously as the very paradigm of a slowly metabolized piece of membrane architecture. Light is now being shed on the functional roles of individual members of the PKC family, and an understanding of how this family meshes with most of these phospholipid signaling stories must surely be approaching. The complexities and uncertainties of phospholipid signaling that we have outlined above are merely the sign of a field begin ning the transition into full flower, a prospect to be viewed with enthusiasm and excitement.
